Abcuro, Inc.
CompanyUnited States
Abcuro, Inc. develops one asset, in phase 2 (ABC008 in inclusion body myositis). Mostly antibody acting on inflammation, cellular senescence and KLRG1; based in the United States.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 1
- Signals
- 0
Pipeline
1Monoclonal antibody targeting killer cell lectin-like receptor G1 (KLRG1) to deplete cytotoxic T cells
Phase 2AntibodyInflammationCellular senescenceinclusion body myositis
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials1
- Similar companies6
Updated 7 Oct 2026 · 2 sources